AZ BioSense Community of Practice

The mission of the Arizona BioSense Workgroup is to work collaboratively as partners to build capacity and quality of BioSense syndromic surveillance in Arizona. Our vision is to improve population health and emergency response through the use of timely and effective syndromic surveillance. This space is a platform for our members to continue discussions and share cross-role topics and questions from providing the data to using syndromic data (clinician/IT/public health).

2020 CDC Releases New Vaccine-Associated Adverse Events ESSENCE Query

Hi All,

On December 11, 2020, the Advisory Committee on Immunization Practices recommended the Pfizer-BioNTech COVID-19 vaccine for persons in the United States age 16 years and older. To ensure that the benefits outweigh the risks for persons who receive the vaccine, several vaccine safety monitoring systems are in place to watch for possible side effects (adverse events): https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html.

To further support these systems, state and local partners of the National Syndromic Surveillance Program (NSSP) have expressed interest in exploring the use of emergency department (ED) data to monitor safety. In response and to assist in these efforts, CDC NSSP has released the first version of a query designed to identify mentions of adverse events after recent vaccination (VAE) during ED visits or in ambulatory healthcare settings. This query (syntax attached)—CDC Vaccine-Associated Adverse Events v1 can be found in the ESSENCE “CC and DD Category” field.
 
The query includes a broad combination of diagnosis codes (ICD-10, ICD-9, and SNOMED) and chief complaint terms to detect visits potentially related to an adverse reaction after recent vaccination (e.g., poisoning, anaphylactic reaction, infection, post-vaccination fever, meningoencephalitis). This query does not attempt to identify specific clinical outcomes.

Given that discharge diagnosis can lag after chief complaint and is occasionally less complete, the NSSP team included chief complaint terms to improve timeliness and provide detailed reason-for-visit information. The chief complaint terms are designed to be more sensitive than specific and could identify ED visits unrelated to a recent vaccination or associated adverse event. 


Comments & Events

Krystal Collier, Syndromic Surveillance Program Coordinator
Recommendations for using this query specifically for the COVID-19 vaccine from Pfizer and Moderna, Zach Stein, from NSSP has provided the following guidance:

"With the existing VAE query, we didn't want to explicitly limit it to vaccine names/types/targets because of the often lack of those data points in CCs. Doesn't mean they won't be there, but for the best national picture and query that works best across multiple jurisdictions we felt being non-specific in that way was important.

You aren't the first to bring up a query of this type though so I plan to bring it up in our discussions and see where it falls on priorities. That being said, this query would be very simple to modify and it wouldn't take a full re-run of the query if you wanted to customize it for your ideas. You could select the CCDD Category, and then add a CC query for something like ^Covid^,or,^Corona v^,or,^Coronav^,or,^moderna^,or,^Pfizer^

That would link the two fields with an "AND" so you'd still get the speedy processing time of the CCDD Category and just be tacking a few extra "AND" requirements onto it.

Thanks!
Zach"


You can also hear more on about these suggestions during the December Syndrome Definition Subcommittee Call when posted to the Knowledge Repository: https://knowledgerepository.syndromicsurveillance.org/syndrome-definition-committee
Krystal Collier, Syndromic Surveillance Program Coordinator
New update from NSSP on suggested ways to use the CDC VAE v1 CCDD category and for looking at COVID-19 Vaccine Adverse Events. 

The ADHS Syndromic Surveillance Team are asking additional information on this new guidance for training purposes such as visualizations for setting these queries and what surveillance questions do each of the approaches answers, etc.  Any questions that you all have, please comment below and we can ask NSSP.

As we understand more about these recommendations we will provide training on future Exploratory Analysis Subgroup/AZ BioSense Opioid Workgroup Calls.
 
Krystal
Mark Person
I use it in the following ways:

1. To map out facilities by count of adverse events. Shows concentrations of COVID specific reactions by hospital or ED.

2. I run the report to catch all the adverse events, then filter out non-covid vaccines. Then search for Pfizer, Moderna, COVID, Corona, etc.

3. Once complete the identified patients can be checked against recent deaths, previous COVID infections, severe illness, comorbidities, etc.

4. I collect all the case details in condensed excel file showing only the following: BP, Temp, O2, BMI, DX, ED, Inpatient, total days/hours, and full clinical summary. This is provided to an internal physician group to review and follow up as needed.
Krystal Collier, Syndromic Surveillance Program Coordinator
Thanks Mark.  This helps in what I can share with NSSP and to a meeting we are having with our team.  I have some clarifications about this second suggested approach from NSSP that I am hoping to get some additional feedback on.